HCW Biologics 10-Q: $3.2M Q3 Loss, Two Unremediated Material Weaknesses, Going Concern Stands
HCWB is trading near its 52-week low of $0.764 (2.0% above the low) on light trading volume (0.1× avg).
Summary
HCW Biologics' Q3 10-Q confirms a $3.2 million quarterly loss and $955,458 of cash with the going concern warning intact, and newly discloses that two material weaknesses in internal controls remain unremediated.
Key Events · Earnings and Guidance · HCWB
-
Q3 Loss Narrows on Trimmune Revenue
Net loss was $3.2 million for Q3 2026 versus $4.6 million a year earlier, while nine-month revenue reached $6.7 million versus $27,222 in 2025, driven by the Trimmune license closing.
-
Cash Falls to $955,458
Cash and cash equivalents dropped from $1,952,464 at December 31, 2025 to $955,458 at September 30, 2026, while accounts payable stood at $9.4 million.
-
Two Material Weaknesses Unremediated
Management concluded disclosure controls were not effective at September 30, 2026, with the long-lived asset impairment and complex warrant accounting weaknesses still open; the March 31, 2026 quarterly report was previously amended for an EPS misstatement.
-
Going Concern Warning Reiterated
Substantial doubt about the ability to continue as a going concern for at least 12 months remains, with cumulative net losses of $110.8 million since inception.
Analysis · HCWB · Life Sciences
The headline numbers match the 8-K filed minutes earlier, but the full quarterly report adds two things investors did not have: both previously reported material weaknesses in internal control over financial reporting remain unremediated as of September 30, 2026, and management concluded disclosure controls were not effective. Against $955,458 of cash and $9.4 million of accounts payable, the company is now marketing its Miramar property at a $15.0 million asking price while forbearance talks with Cogent Bank and lienholders are still unfinished, and it faces a fresh arbitration demand from a placement agent over unpaid tail fees. The going concern warning is unchanged, and the $10 million Streeterville facility is expected to carry operations only to the Q1 2027 HCW9302 Phase 1 readout.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCWB was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.76 to $23.94. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.